Maternal Mental Health Awareness Week: May 1-7, 2024
May 1, 2024 is World Maternal Mental Health Day, coming together to increase awareness of perinatal mood and anxiety disorders.
FDA Clears Digital Therapeutic for the Treatment of Postpartum Depression
MamaLift Plus is a prescription-only digital therapeutic intervention for the treatment of mild to moderate postpartum depression using several different neurobehavioral interventions.
Depression During Pregnancy Is a Risk Factor for Postpartum Depression, Does Timing Matter?
Women who experienced depression during pregnancy were about four times as likely to experience PPD compared to women with no depression during pregnancy, with greater risk associated with depression during the first and third trimesters.
Treatment of PPD with SSRIs: Long-Term Benefits for Both Mother and Child
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
What is Dexmedetomidine? And Does it Prevent Postpartum Depression?
Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.
Is Postpartum Depression More Common in Women with Sensitivity to Hormonal Contraceptive?
A history of hormonal contraception-associated depression may be associated with a higher risk for postpartum depression.
Essential Reads: Postpartum Depression, Is it Unipolar or Bipolar?
Vigilance is required in screening women who present with postpartum depression; a subset of women who screen positive for depression may actually have bipolar disorder.
You Asked: How Worrisome is the Boxed Warning for the New Postpartum Depression Medication?
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Toward a better framework for postmarketing reproductive safety surveillance of medications
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.